{
    "Trade/Device Name(s)": [
        "Aina HbA1c Monitoring System 2"
    ],
    "Submitter Information": "Jana Care, Inc.",
    "510(k) Number": "K192987",
    "Predicate Device Reference 510(k) Number(s)": [
        "K151809"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCP"
    ],
    "Summary Letter Date": "March 26, 2020",
    "Summary Letter Received Date": "February 21, 2020",
    "Submission Date": "February 20, 2020",
    "Regulation Number(s)": [
        "21 CFR 864.7470"
    ],
    "Regulation Name(s)": [
        "Glycosylated Hemoglobin Assay"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "HbA1c",
        "Glycosylated hemoglobin"
    ],
    "Specimen Type(s)": [
        "Anticoagulated venous whole blood"
    ],
    "Specimen Container(s)": [
        "K2-EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Aina 2 Automated HbA1c Device",
        "Aina Device",
        "Mobile device running Aina Mobile Application"
    ],
    "Method(s)/Technology(ies)": [
        "Boronate affinity",
        "Reflectance-based colorimetric sensor"
    ],
    "Methodologies": [
        "Quantitative measurement of glycosylated hemoglobin"
    ],
    "Submission Type(s)": [
        "System",
        "Device",
        "Test Kit",
        "Application",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for Jana Care Aina HbA1c Monitoring System 2 using boronate affinity method and colorimetric detection to measure HbA1c in human venous whole blood.",
    "Indications for Use Summary": "Quantitative measurement of %HbA1c and mmol/mol HbA1c in human anticoagulated venous whole blood by healthcare professionals in laboratory settings to monitor long-term glycemic control in persons previously diagnosed with diabetes; not for diagnosis or screening of diabetes or use on neonates.",
    "fda_folder": "Hematology"
}